Saracatinib difumarate is under clinical development by AstraZeneca and currently in Phase I for Psychosis. According to GlobalData, Phase I drugs for Psychosis have a 59% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Saracatinib difumarate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Saracatinib difumarate overview
Saracatinib difumarate (AZD-0530) is under development for the treatment of Parkinson's disease psychosis, idiopathic pulmonary fibrosis and fibrodysplasia ossificans progressiva. The drug candidate is administered orally in the form of tablet. Saracatinib targets Fyn kinase, SRC/Abl kinase. The drug candidate is a substituted anilinoquinazoline with anti-invasive and anti-tumor activities.
It was also under development for the treatment of hematological malignancies and solid tumors which includes colorectal cancer, ovarian cancer, prostate cancer, non-small cell lung cancer or breast cancer with metastatic bone disease, osteosarcoma cancer induced bone pain, Alzheimer's disease, lymphangioleiomyomatosis and alcohol addiction.
AstraZeneca overview
AstraZeneca is a biopharmaceutical company, which is focused on discovery, production and commercialization of a range of prescription drugs. It develops products related to therapy areas such as respiratory, cardiovascular, renal and metabolic diseases, cancer, autoimmune, infection and neurological diseases. The company’s product portfolio includes biologics, prescription pharmaceuticals and vaccines. AstraZeneca sells its products through wholly- owned local marketing companies, distributors and local representative offices. The company markets its products to primary care and specialty care physicians. The company operates in Europe, the Americas, Asia, Africa and Australasia. AstraZeneca is headquartered in Cambridge, Cambridgeshire, the UK.
For a complete picture of Saracatinib difumarate’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
